- Home
- PDSB vs CLSD Comparison
PDSB vs CLSD Comparison
Compare PDSB & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- CLSD
- Stock Information
- Founded
- PDSB 2005
- CLSD 2011
- Country
- PDSB United States
- CLSD United States
- Employees
- PDSB N/A
- CLSD N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- PDSB Health Care
- CLSD Health Care
- Exchange
- PDSB Nasdaq
- CLSD Nasdaq
- Market Cap
- PDSB 72.2M
- CLSD 59.1M
- IPO Year
- PDSB N/A
- CLSD 2016
- Fundamental
- Price
- PDSB $1.24
- CLSD $0.87
- Analyst Decision
- PDSB Strong Buy
- CLSD Strong Buy
- Analyst Count
- PDSB 2
- CLSD 4
- Target Price
- PDSB $10.00
- CLSD $4.75
- AVG Volume (30 Days)
- PDSB 473.1K
- CLSD 179.1K
- Earning Date
- PDSB 08-12-2025
- CLSD 08-11-2025
- Dividend Yield
- PDSB N/A
- CLSD N/A
- EPS Growth
- PDSB N/A
- CLSD N/A
- EPS
- PDSB N/A
- CLSD N/A
- Revenue
- PDSB N/A
- CLSD $3,764,000.00
- Revenue This Year
- PDSB N/A
- CLSD $60.52
- Revenue Next Year
- PDSB N/A
- CLSD $88.28
- P/E Ratio
- PDSB N/A
- CLSD N/A
- Revenue Growth
- PDSB N/A
- CLSD N/A
- 52 Week Low
- PDSB $0.85
- CLSD $0.70
- 52 Week High
- PDSB $4.42
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- PDSB 39.29
- CLSD 58.96
- Support Level
- PDSB $1.20
- CLSD $0.80
- Resistance Level
- PDSB $1.40
- CLSD $0.88
- Average True Range (ATR)
- PDSB 0.10
- CLSD 0.04
- MACD
- PDSB -0.03
- CLSD 0.01
- Stochastic Oscillator
- PDSB 12.50
- CLSD 84.82
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.